Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study

EBioMedicine

Volumn 3, Issue , 2016, Pages 135-140

  Gisslén, Magnus ^a   Price, Richard W ^b   Andreasson, Ulf ^a   Norgren, Niklas ^c   Nilsson, Staffan ^d   Hagberg, Lars ^a   Fuchs, Dietmar ^e   Spudich, Serena ^f   Blennow, Kaj ^a   Zetterberg, Henrik ^a,g  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UmanDiagnostics AB   (Sweden)

^d CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antiretroviral Treatment; Biomarker; Central Nervous System; Cerebrospinal Fluid; CNS; CSF; HAD; HIV; HIV Associated Dementia; Neurofilament Light Chain; NFL; Plasma

Indexed keywords

ANTIRETROVIRUS AGENT; NEUROFILAMENT LIGHT PROTEIN; NEUROFILAMENT PROTEIN; UNCLASSIFIED DRUG; VIRUS RNA; BIOLOGICAL MARKER; NEUROFILAMENT PROTEIN L;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CNS INJURY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MIDDLE AGED; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM VIRAL DISEASES; CEREBROSPINAL FLUID; COMPLICATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; MALE; SENSITIVITY AND SPECIFICITY; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOMARKERS; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM VIRAL DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEUROFILAMENT PROTEINS; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

EID: 84958936131     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.11.036     Document Type: Article

References (30)

1. Anon. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology 1991, 41(6):778-785.
2. Antinori A., Arendt G., Becker J.T., et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007, 69(18):1789-1799.
3. Canestri A., Lescure F.X., Jaureguiberry S., et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin. Infect. Dis. 2010, 50(5):773-778.
4. Constantinescu R., Rosengren L., Johnels B., Zetterberg H., Holmberg B. Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders. Parkinsonism Relat. Disord. 2010, 16(2):142-145.
5. Gisslen M., Fuchs D., Svennerholm B., Hagberg L. Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J. Acquir. Immune Defic. Syndr. 1999, 21(4):271-276.
6. Gisslen M., Hagberg L., Brew B.J., Cinque P., Price R.W., Rosengren L. Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J. Infect. Dis. 2007, 195(12):1774-1778.
7. Grahn A., Hagberg L., Nilsson S., Blennow K., Zetterberg H., Studahl M. Cerebrospinal fluid biomarkers in patients with varicella-zoster virus CNS infections. J. Neurol. 2013, 260(7):1813-1821.
8. Gunnarsson M., Malmestrom C., Axelsson M., et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann. Neurol. 2011, 69(1):83-89.
9. Hagberg L., Cinque P., Gisslen M., et al. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res. Ther. 2010, 7:15.
10. Heaton R.K., Clifford D.B., Franklin D.R., et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology 2010, 75(23):2087-2096.
11. Heaton R.K., Franklin D.R., Ellis R.J., et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J. Neurovirol. 2011, 17(1):3-16.
12. Hoffman P.N., Cleveland D.W., Griffin J.W., Landes P.W., Cowan N.J., Price D.L. Neurofilament gene expression: a major determinant of axonal caliber. Proc. Natl. Acad. Sci. U. S. A. 1987, 84(10):3472-3476.
13. Jessen Krut J., Mellberg T., Price R.W., et al. Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients. PLoS One 2014, 9(2):e88591.
14. Jonsson M., Zetterberg H., van Straaten E., et al. Cerebrospinal fluid biomarkers of white matter lesions - cross-sectional results from the LADIS study. Eur. J. Neurol. 2010, 17(3):377-382.
15. Lescure F.X., Omland L.H., Engsig F.N., et al. Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study. Clin. Infect. Dis. 2011, 52(2):235-243.
16. Lu C.H., Macdonald-Wallis C., Gray E., et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology 2015, 84(22):2247-2257.
17. Munoz-Moreno J.A., Fumaz C.R., Ferrer M.J., et al. Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res. Hum. Retrovir. 2008, 24(10):1301-1307.
18. Norgren N., Rosengren L., Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res. 2003, 987(1):25-31.
19. Peluso M.J., Ferretti F., Peterson J., et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS 2012, 26(14):1765-1774.
20. Peluso M.J., Meyerhoff D.J., Price R.W., et al. Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J. Infect. Dis. 2013, 207(11):1703-1712.
21. Peterson J., Gisslen M., Zetterberg H., et al. Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection. PLoS One 2014, 9(12):e116081.
22. Price R.W., Brew B.J. The AIDS dementia complex. J. Infect. Dis. 1988, 158(5):1079-1083.
23. Price R.W., Brew B., Sidtis J., Rosenblum M., Scheck A.C., Cleary P. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science 1988, 239(4840):586-592.
24. Price R.W., Paxinos E.E., Grant R.M., et al. Cerebrospinal fluid response to structured treatment interruption after virological failure. AIDS 2001, 15(10):1251-1259.
25. Rissin D.M., Kan C.W., Campbell T.G., et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat. Biotechnol. 2010, 28(6):595-599.
26. Skillback T., Farahmand B., Bartlett J.W., et al. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology 2014, 83(21):1945-1953.
27. Spudich S., Gisslen M., Hagberg L., et al. Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J. Infect. Dis. 2011, 204(5):753-760.
28. Studahl M., Rosengren L., Gunther G., Hagberg L. Difference in pathogenesis between herpes simplex virus type 1 encephalitis and tick-borne encephalitis demonstrated by means of cerebrospinal fluid markers of glial and neuronal destruction. J. Neurol. 2000, 247(8):636-642.
29. Trojanowski J.Q., Walkenstein N., Lee V.M. Expression of neurofilament subunits in neurons of the central and peripheral nervous system: an immunohistochemical study with monoclonal antibodies. J. Neurosci. 1986, 6(3):650-660.
30. Valcour V., Chalermchai T., Sailasuta N., et al. Central nervous system viral invasion and inflammation during acute HIV infection. J. Infect. Dis. 2012, 206(2):275-282.